Vitamin supplementation as a potential adjunctive therapeutic approach for COVID-19: biological and clinical plausibility
Abstract The recent pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19) has introduced itself into the human population in the 21st century after the coronavirus diseases SARS-CoV and Middle East respiratory syndrome (MERS-CoV). Major investigations are underway worldwide in the search for pharmaceutical interventions for COVID-19 and many agents are administered in off-label routes. Several cases are under study to check or restrict clinical manifestations of COVID-19. According to the fact that the efficacy of some micro-nutrients like vitamins is proven to treat or prevent infectious diseases because of their antimicrobial and immunomodulatory activity, the potential role of vitamins in the COVID-19 treatment or prevention must be considered..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Journal of basic and clinical physiology and pharmacology - 33(2021), 1 vom: 09. Aug., Seite 55-77 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Daei Sorkhabi, Amin [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 Walter de Gruyter GmbH, Berlin/Boston |
|---|
| doi: |
10.1515/jbcpp-2021-0111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY008864594 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY008864594 | ||
| 003 | DE-627 | ||
| 005 | 20231205155605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230813s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/jbcpp-2021-0111 |2 doi | |
| 035 | |a (DE-627)GRUY008864594 | ||
| 035 | |a (DE-B1597)jbcpp-2021-0111-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Daei Sorkhabi, Amin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vitamin supplementation as a potential adjunctive therapeutic approach for COVID-19: biological and clinical plausibility |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 Walter de Gruyter GmbH, Berlin/Boston | ||
| 520 | |a Abstract The recent pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19) has introduced itself into the human population in the 21st century after the coronavirus diseases SARS-CoV and Middle East respiratory syndrome (MERS-CoV). Major investigations are underway worldwide in the search for pharmaceutical interventions for COVID-19 and many agents are administered in off-label routes. Several cases are under study to check or restrict clinical manifestations of COVID-19. According to the fact that the efficacy of some micro-nutrients like vitamins is proven to treat or prevent infectious diseases because of their antimicrobial and immunomodulatory activity, the potential role of vitamins in the COVID-19 treatment or prevention must be considered. | ||
| 700 | 1 | |a Sarkesh, Aila |4 aut | |
| 700 | 1 | |a Daei Sorkhabi, Alireza |4 aut | |
| 700 | 1 | |a Entezari-Maleki, Taher |4 aut | |
| 700 | 1 | |a Rashedi, Jalil |4 aut | |
| 700 | 1 | |a Bannazadeh Baghi, Hossein |0 (orcid)0000-0002-2513-5361 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of basic and clinical physiology and pharmacology |d De Gruyter, 1990 |g 33(2021), 1 vom: 09. Aug., Seite 55-77 |h Online-Ressource |w (DE-627)GRUY000027650 |w (DE-600)2602428-7 |w (DE-576)358409020 |x 2191-0286 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2021 |g number:1 |g day:09 |g month:08 |g pages:55-77 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1515/jbcpp-2021-0111 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.38 |j Pharmakologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 33 |j 2021 |e 1 |b 09 |c 08 |h 55-77 | ||